Cascure Therapeutics develops highly selective anticancer medicines using the CINDELA (Cancer-specific INDELA Attacker) platform, which targets mutation sequences found only in tumor cells. Our mission is to deliver a first-in-class CRISPR-based therapy and give patients a life free from the fear of cancer.

Today, for about KRW 1 million (approximately USD 1,000), clinicians can easily pinpoint the genetic defects in a patient’s cancer cells. Yet, despite many personalized therapies that use this information, cancer remains a formidable disease that endangers patients and their families. Metastasis and recurrence, in particular, cause a large share of cancer-related deaths and continue to instill fear.

Cascure has combined tumor-genome insights with CRISPR gene editing to create the CINDELA platform. CINDELA continues to work without resistance even in cases of recurrence and metastasis. This new therapy has fewer side effects and can be offered to patients at a lower cost than traditional cancer treatments.